BCLAF1 Antibody

What is BCLAF1 and why is it important in cellular research?

BCLAF1, also known as BTF, is a 920 amino acid protein that localizes to both the nucleus and cytoplasm. It functions as a death-promoting transcriptional repressor of survival genes through interaction with several members of the BCL2 family of proteins. BCLAF1 shows homology to the basic leucine zipper (bZip) and Myb DNA binding domains and can bind DNA in vitro .

BCLAF1 is critically involved in multiple cellular processes:

• Apoptosis regulation through interaction with Bcl-2

• DNA damage response and repair mechanisms

• Type I interferon signaling and antiviral immunity

• T cell activation and immune system function

• Lung development and tissue homeostasis

BCLAF1 knockout mice are embryonic lethal due to defects in lung development, highlighting its essential role in developmental processes . The protein undergoes alternative splicing, resulting in four distinct isoforms that may have different regulatory roles in various cellular pathways .

What are the key applications for BCLAF1 antibodies in molecular biology research?

BCLAF1 antibodies are versatile tools used in multiple experimental approaches:

When selecting a BCLAF1 antibody, researchers should consider the specific application and experimental system. For example, the antibody clone AB02/2F2 detects a band of approximately 151 kDa in HEK293 cell lysates and is suitable for Western blotting applications . Meanwhile, some polyclonal antibodies like the one described in source can detect BCLAF1 across multiple species including human, mouse, canine, and chimpanzee samples.

How does BCLAF1 expression vary across different cell types and tissues?

BCLAF1 is widely expressed but shows significant variation across different tissues. While it was initially found to be primarily expressed in skeletal muscle , subsequent research has demonstrated its presence in numerous cell types and tissues:

In hepatocellular carcinoma (HCC), BCLAF1 expression is notably increased compared to normal liver tissues, and elevated levels correlate with advanced tumor grades and diminished survival rates . This expression pattern makes BCLAF1 a potential biomarker for certain cancer types.

For optimal experimental design, researchers should consider these tissue-specific expression patterns when selecting positive and negative controls for antibody validation.

How does BCLAF1 function in antiviral immunity through the type I interferon pathway?

BCLAF1 is a critical regulator in type I interferon (IFN) signaling and antiviral defense mechanisms. Research has revealed its dual functions in the IFN signaling cascade:

• STAT phosphorylation: BCLAF1 maintains a mechanism that enables efficient phosphorylation of STAT1 and STAT2 in response to IFNα stimulation .

• ISGF3 complex facilitation: BCLAF1 interacts with the ISGF3 complex (composed of STAT1, STAT2, and IRF9) in the nucleus, primarily through STAT2, and facilitates the complex's binding to Interferon-Stimulated Response Elements (ISREs) in the promoters of IFN-stimulated genes (ISGs) .

Experimental data from BCLAF1 knockdown or knockout cells demonstrates that:

• Depletion of BCLAF1 significantly impairs IFNα-mediated gene transcription

• BCLAF1 deficiency reduces the expression of ISG15 in response to IFNα treatment

• Cells lacking BCLAF1 show decreased resistance to viral infection when treated with IFNα

This antiviral function explains why multiple herpesviruses have evolved mechanisms to target BCLAF1. In Pseudorabies virus (PRV) and Herpes simplex virus type 1 (HSV-1) infections, the viral protein US3 promotes the degradation of BCLAF1, thereby impairing IFN-mediated antiviral responses .

When designing experiments to study BCLAF1's role in interferon signaling, researchers should consider:

• Using both BCLAF1 knockdown/knockout approaches and overexpression systems

• Evaluating multiple ISGs as readouts for interferon response

• Including appropriate viral infection models, particularly those with known interactions with BCLAF1

What role does BCLAF1 play in cancer progression and resistance to therapy?

BCLAF1 exhibits complex and sometimes contradictory functions in cancer progression, acting as both a tumor suppressor and an oncogene depending on the cancer type and context.

In hepatocellular carcinoma (HCC):

• BCLAF1 expression is elevated compared to normal liver tissues

• Higher BCLAF1 levels correlate with increased tumor grades and reduced survival rates

• BCLAF1 overexpression accelerates tumor growth and lung metastasis in mouse models

• BCLAF1 promotes angiogenesis, as demonstrated by enhanced tube formation capacity of HUVECs exposed to conditioned medium from BCLAF1-overexpressing HCC cells

In lung cancer, BCLAF1 contributes to chemoresistance:

• Expression of BCLAF1 is higher in cisplatin-resistant A549 lung cancer cells (A549/DDP)

• BCLAF1 promotes DNA damage repair in resistant cells

• BCLAF1 interacts with BRCA1 in mediating resistance to DNA damage

Mechanistically, BCLAF1 can affect cancer progression through multiple pathways:

• HIF-1α regulation: BCLAF1 attenuates the expression of prolyl hydroxylase domain protein 2 (PHD2) and governs the stability of HIF-1α under normoxic conditions, promoting PD-L1 transcription. This mechanism may contribute to resistance to immunotherapy in HCC patients .

• c-FLIP regulation: BCLAF1 positively regulates c-FLIP expression via interaction with p50, protecting cells from TNF-mediated apoptosis .

• Alternative splicing regulation: Aberrant alternative splicing of BCLAF1 pre-mRNA appears to be a major contributor to colon cancer development .

Research focusing on BCLAF1 in cancer should consider these diverse and sometimes opposing functions, and carefully control for cancer type, stage, and treatment status when interpreting results.

How can researchers design experiments to investigate BCLAF1's contradictory roles in apoptosis and cell survival?

BCLAF1 exhibits context-dependent functions in both promoting apoptosis and enhancing cell survival, presenting a challenging system to study. Effective experimental design should:

• Control cellular context: Since BCLAF1's function varies by cell type, use multiple cell lines and primary cells. Compare cells with naturally high BCLAF1 expression (e.g., skeletal muscle cells) with those having lower expression.

• Manipulate expression systematically:

  • Use inducible expression systems to control the timing and level of BCLAF1 expression

  • Create both knockdown and knockout models using siRNA/shRNA and CRISPR/Cas9

  • Express different domains of BCLAF1 separately to identify region-specific functions

• Monitor subcellular localization: BCLAF1 function changes based on its localization. In apoptotic cells, it redistributes from dot-like structures throughout the nucleus to a zone near the nuclear envelope . Use fluorescently-tagged BCLAF1 constructs or immunofluorescence with specific antibodies to track localization changes.

• Analyze protein-protein interactions: BCLAF1 interacts with multiple partners including:

  • Anti-apoptotic Bcl-2 family members

  • Nuclear factor-κB (NF-κB) p50 subunit

  • STAT1 and STAT2 in interferon signaling

  • Cullin 3 (CUL3) for PHD2 degradation

• Assess functional outcomes using multiple assays:

When interpreting conflicting results, consider that BCLAF1's pro-apoptotic effects are evident in overexpression systems, while its pro-survival functions may dominate in physiological expression contexts or specific signaling environments such as interferon stimulation .

What are the optimal protocols for BCLAF1 immunoprecipitation to study its binding partners?

Effective immunoprecipitation (IP) of BCLAF1 requires careful consideration of buffer conditions, antibody selection, and experimental controls. Based on published research, the following protocol has proven successful:

Recommended IP Protocol for BCLAF1:

• Cell Lysis and Fractionation:

  • For total cell lysates: Lyse cells in RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) with protease and phosphatase inhibitors

  • For nuclear/cytoplasmic fractionation: Use a gentle lysis buffer (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5% NP-40) for cytoplasmic extraction, followed by nuclear extraction buffer (20 mM HEPES pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT)

• Antibody Selection:

  • For human BCLAF1: Multiple antibodies have been validated for IP, including the polyclonal rabbit anti-BCLAF1 antibody (Cat. #151459) and mouse monoclonal antibody M33-P5B11

  • For studies across species: Use antibodies with demonstrated cross-reactivity, such as PA1-41680 which detects BCLAF1 in human, mouse, canine, and chimpanzee samples

• IP Procedure:

  • Pre-clear lysates with protein A/G beads for 1 hour at 4°C

  • Incubate lysates with 2-5 μg antibody overnight at 4°C

  • Add protein A/G beads for 2-4 hours

  • Wash beads 3-5 times with lysis buffer containing reduced detergent

  • Elute proteins with SDS sample buffer or by competitive elution if maintaining activity is important

• Critical Controls:

  • IgG control of the same species as the primary antibody

  • Lysate from BCLAF1 knockdown or knockout cells as a negative control

  • Input sample (typically 5-10% of the amount used for IP)

Important Considerations Based on Research Findings:

When studying interactions with specific partners, modify the protocol based on the following insights:

• For p50 interactions: Nuclear fractionation is essential as BCLAF1-p50 complexes are predominantly nuclear. TNF treatment (2 hours) enhances this interaction

• For STAT1/STAT2 interactions: IFNα treatment significantly increases these interactions. Crosslinking with formaldehyde (1%) prior to lysis can help preserve these interactions

• For CUL3 interactions: These occur under normoxic conditions and are important for PHD2 degradation and HIF-1α stabilization

What strategies can researchers use to study different BCLAF1 isoforms resulting from alternative splicing?

BCLAF1 undergoes alternative splicing to produce four distinct isoforms that may have different functional roles. Designing experiments to distinguish between these isoforms requires specific approaches:

• Isoform-Specific Detection by Western Blotting:

  • Select antibodies that can detect all isoforms (e.g., those targeting common regions)

  • Use high-resolution gels (6-8% polyacrylamide) to separate closely sized isoforms

  • Include positive controls for each isoform, ideally from tissues known to express specific variants

• Transcript Analysis:

  • Design PCR primers spanning exon-exon junctions unique to each isoform

  • Employ RT-qPCR with isoform-specific primers for quantitative analysis

  • Consider RNA-seq analysis with computational approaches specifically designed to quantify splice variants

• Expression Systems for Functional Studies:

  • Clone individual BCLAF1 isoforms into expression vectors

  • Use epitope tags that won't interfere with protein function

  • Create stable cell lines expressing single isoforms for comparative studies

• Domain-Specific Functional Analysis:

  • The middle region (F2) of BCLAF1 has been shown to interact with p50 and is required for transcriptional activation of CFLAR

  • Create domain-specific mutants to investigate the functional contributions of each region

• Context-Dependent Analysis:

  • BCLAF1 isoform expression may vary by tissue type and cellular conditions

  • Investigate isoform expression in different contexts (e.g., normal vs. cancer tissues, before vs. after stress stimuli)

Example of Isoform Analysis in Cancer Research:

Research has indicated that aberrant alternative splicing of BCLAF1 pre-mRNA contributes to colon cancer development . When investigating this phenomenon:

• Compare BCLAF1 isoform patterns between normal colon tissue and colon cancer samples

• Correlate specific isoform expression with clinical parameters

• Investigate mechanisms regulating splice site selection in normal vs. cancer cells

• Assess functional consequences of each isoform on cancer-relevant phenotypes (proliferation, migration, apoptosis resistance)

How should researchers optimize immunofluorescence protocols for BCLAF1 to accurately detect its subcellular localization?

BCLAF1 exhibits dynamic subcellular localization that changes in response to cellular conditions—particularly during apoptosis and viral infection. Optimizing immunofluorescence protocols is essential for accurate localization studies:

Optimal Immunofluorescence Protocol for BCLAF1:

• Fixation Options:

  • Paraformaldehyde (4%) fixation for 15 minutes at room temperature preserves most epitopes

  • For certain applications, methanol fixation (-20°C for 10 minutes) may better preserve nuclear architecture

  • Avoid over-fixation which can mask epitopes and increase background

• Permeabilization Methods:

  • For cytoplasmic and nuclear BCLAF1: 0.2% Triton X-100 for 10 minutes

  • For better nuclear detail: 0.5% Triton X-100 with a shorter incubation (5 minutes)

  • Alternative: 0.05% saponin if gentler permeabilization is needed

• Blocking Conditions:

  • 5% normal serum (matching the host species of the secondary antibody)

  • 1% BSA in PBS

  • Include 0.1% Triton X-100 to maintain permeabilization

• Antibody Selection and Dilution:

  • Primary antibodies: Start with manufacturer's recommended dilution and optimize

  • Well-validated antibodies include mouse monoclonal M33-P5B11 and rabbit polyclonal PA1-41680

  • Secondary antibodies: Highly cross-adsorbed variants to minimize non-specific binding

• Counterstaining:

  • Nuclear stain: DAPI or Hoechst (essential for correlating with BCLAF1's nuclear patterns)

  • Consider co-staining with markers of nuclear subdomains (e.g., SC35 for nuclear speckles)

  • For apoptosis studies: Include apoptotic markers like cleaved caspase-3

Special Considerations Based on Research Findings:

• Dot-like Nuclear Structures: Under normal conditions, BCLAF1 localizes in dot-like structures throughout the nucleus. In apoptotic cells, it redistributes to a zone near the nuclear envelope . Use confocal microscopy with Z-stacks to accurately capture these patterns.

• Viral Infection Studies: During PRV and HSV-1 infection, BCLAF1 degradation occurs through viral protein US3 . For these studies:

  • Include appropriate time points post-infection

  • Co-stain for viral markers

  • Use US3-deficient viral strains as controls

• Cancer Cell Studies: In certain cancer contexts, BCLAF1 localization may be altered. For example, in HCC with elevated BCLAF1 expression, evaluate both nuclear and cytoplasmic distribution and correlate with disease parameters .

• Dynamic Relocalization: To capture BCLAF1's dynamic relocalization in response to stimuli:

  • Consider live-cell imaging with fluorescently tagged BCLAF1

  • Use time-course experiments with fixed cells at multiple time points

  • Employ drug treatments that block nuclear import/export to validate trafficking mechanisms

What are the common sources of false positives and negatives when using BCLAF1 antibodies in Western blotting?

Western blotting for BCLAF1 can present several challenges leading to false results. Understanding these issues is critical for accurate data interpretation:

Common Sources of False Positives:

• Cross-reactivity with similar proteins:

  • BCLAF1 shares structural domains with other transcription factors

  • Solution: Verify specificity with BCLAF1 knockout/knockdown controls

  • Alternative: Use multiple antibodies targeting different epitopes

• Degradation products:

  • BCLAF1 is subject to proteolytic degradation, particularly during viral infections

  • These fragments may appear as additional bands

  • Solution: Use fresh samples with complete protease inhibitor cocktails

  • Interpretation: Document consistent fragment patterns and compare with literature

• Non-specific binding:

  • High antibody concentrations can increase background

  • Solution: Optimize antibody dilutions (typical range: 1:500-1:2000)

  • Alternative: Use longer blocking steps (2 hours at room temperature or overnight at 4°C)

Common Sources of False Negatives:

• Epitope masking:

  • Post-translational modifications may mask epitopes

  • Solution: Try antibodies targeting different regions of BCLAF1

  • Alternative: Use phosphatase treatment if phosphorylation is suspected

• Low expression levels:

  • BCLAF1 expression varies across tissues and conditions

  • Solution: Load more protein (50-100 μg) or use enrichment methods

  • Alternative: Consider more sensitive detection methods (e.g., chemiluminescent substrates)

• Inefficient transfer of high-molecular-weight proteins:

  • BCLAF1 is a large protein (~151 kDa)

  • Solution: Use overnight transfer at lower voltage or wet transfer systems

  • Alternative: Add SDS (0.1%) to transfer buffer to improve elution of large proteins

Optimization Recommendations:

Special Considerations for BCLAF1:

• When studying viral infection models, the degradation of BCLAF1 by viral proteins like US3 may result in reduced signal intensity or altered banding patterns

• In cancer studies, be aware that BCLAF1 expression may be significantly elevated, requiring adjustment of loading amounts to avoid signal saturation

How can researchers reconcile contradictory findings between different experimental models when studying BCLAF1 function?

The literature contains apparently contradictory findings regarding BCLAF1 function, particularly in apoptosis, cancer progression, and immune response. Reconciling these discrepancies requires systematic analysis of experimental variables:

Key Sources of Experimental Variation:

• Cell Type and Tissue Specificity:

  • BCLAF1 exhibits different functions in different cell types

  • Lung tissue: Essential for development and organization of smooth muscle

  • Immune cells: Critical for T-cell homeostasis

  • Cancer cells: Context-dependent roles in promoting or inhibiting tumor growth

  Recommendation: Always compare results across multiple cell types and primary tissues

• Expression Level Considerations:

  • Overexpression systems often show pro-apoptotic effects

  • Physiological expression levels may reveal different functions

  • The ratio of BCLAF1 to its binding partners affects outcomes

  Recommendation: Use inducible expression systems and titrate expression levels

• Experimental Context and Stimuli:

  • Interferon stimulation reveals BCLAF1's role in antiviral immunity

  • TNF treatment highlights its interaction with p50 and protection from apoptosis

  • DNA damage response shows its role in repair mechanisms

  Recommendation: Systematically test multiple stimuli in the same experimental system

• Isoform Variation:

  • Four BCLAF1 isoforms exist due to alternative splicing

  • Different isoforms may have distinct or even opposing functions

  Recommendation: Specify which isoform(s) are being studied and verify expression

Analytical Framework for Reconciliation:

When facing contradictory results, apply this systematic approach:

• Meta-analysis of published studies:

  • Create a comparison table of experimental conditions, cell types, and stimuli

  • Identify patterns that explain different outcomes

  • Look for consensus in specific contexts

• Direct replication with controlled variables:

  • Replicate published protocols with precise documentation

  • Systematically modify one variable at a time

  • Include appropriate positive and negative controls

• Integrative multi-omics approach:

  • Combine transcriptomics, proteomics, and functional assays

  • Look for condition-specific protein-protein interactions

  • Create network models that account for context-dependent functions

Example of Reconciliation in Apoptosis Research:

BCLAF1 has been reported as both pro-apoptotic and anti-apoptotic. These seemingly contradictory findings can be explained by:

• Overexpression vs. knockdown: Overexpression induces apoptosis by preventing Bcl-2 transcription , while physiological levels support normal cell function

• Cellular context: In the context of TNF signaling, BCLAF1 protects against apoptosis by regulating c-FLIP via p50

• Subcellular localization: The pro-apoptotic function correlates with nuclear envelope accumulation, while dispersed nuclear localization associates with other functions

By systematically evaluating these factors, researchers can develop more nuanced and accurate models of BCLAF1 function across different biological contexts.

What are best practices for validating BCLAF1 antibody specificity in new experimental systems?

Proper validation of BCLAF1 antibodies is crucial, especially when working with new experimental systems or studying complex biological questions. Follow these comprehensive validation strategies:

Antibody Validation Workflow:

• Initial Literature and Database Review:

  • Search for published validations of the specific antibody clone

  • Check antibody validation databases (e.g., Antibodypedia, CiteAb)

  • Review vendor technical data including Western blot images

• Essential Positive and Negative Controls:

  • Genetic controls: Include BCLAF1 knockout or knockdown samples

  • Expression controls: Use cells with known BCLAF1 expression levels

  • Cross-species controls: If studying non-human systems, confirm specificity

  • Recombinant protein: Use purified BCLAF1 as a size reference

• Multi-technique Validation Approach:

• Application-Specific Validation:

  • For ChIP applications: Verify enrichment at known BCLAF1 binding sites

  • For flow cytometry: Compare with isotype controls and blocking peptides

  • For tissue IHC: Include tissue with known expression patterns

Special Considerations for BCLAF1:

• Isoform Detection:

  • Determine which BCLAF1 isoforms are recognized by your antibody

  • When possible, use antibodies that can detect all four known isoforms

  • For isoform-specific studies, validate with recombinant isoform proteins

• Post-translational Modifications:

  • BCLAF1 undergoes various modifications including phosphorylation

  • These modifications may affect antibody recognition

  • Consider using phospho-specific antibodies when studying signaling events

• Viral Infection Studies:

  • BCLAF1 is targeted for degradation by viral proteins like US3

  • Validate antibody detection of degradation products

  • Include time-course studies to demonstrate dynamic changes

• Species Cross-Reactivity:

  • Some antibodies like PA1-41680 detect BCLAF1 across multiple species

  • Others may be species-specific

  • Always validate cross-reactivity experimentally, even if claimed by vendor

Example Validation Protocol:

For a comprehensive validation of a new BCLAF1 antibody in human cancer cell lines:

• Run Western blots with:

  • Control cell lines with known BCLAF1 expression

  • BCLAF1 knockdown/knockout cells

  • Multiple human cancer cell lines to assess expression variation

• Confirm specificity via:

  • IP-MS to identify all proteins pulled down

  • Western blot of IP samples with an alternative BCLAF1 antibody

  • Competition with immunizing peptide

• Validate functional relevance:

  • Immunofluorescence to confirm expected nuclear localization pattern

  • Co-localization with known BCLAF1 interacting partners

  • Response to stimuli known to affect BCLAF1 (e.g., IFNα treatment)

By applying these rigorous validation strategies, researchers can ensure the reliability and reproducibility of their BCLAF1 antibody-based experiments.

What emerging applications of BCLAF1 antibodies are anticipated in cancer immunotherapy research?

Recent findings suggest promising new applications for BCLAF1 antibodies in cancer immunotherapy research, particularly in the context of resistance mechanisms and patient stratification:

The discovery that BCLAF1 expression is elevated in hepatocellular carcinoma (HCC) patients who were not responsive to the combined treatment of atezolizumab (anti-PD-L1) and bevacizumab (anti-VEGF) opens significant avenues for research . This correlation suggests several important research directions:

• Predictive Biomarker Development:

  • Standardization of BCLAF1 detection protocols in clinical samples

  • Determination of optimal cutoff values for BCLAF1 expression that predict immunotherapy response

  • Development of companion diagnostic assays using validated BCLAF1 antibodies

• Resistance Mechanism Investigation:

  • Further elucidation of the BCLAF1-HIF-1α-PD-L1 axis under normoxic conditions

  • Analysis of how BCLAF1 overexpression counteracts PD-L1 blockade therapy

  • Exploration of potential combination therapies targeting both BCLAF1 and PD-L1

• Therapeutic Targeting Strategies:

  • Design of small molecule inhibitors or peptide antagonists of BCLAF1 function

  • Development of targeted degradation approaches (e.g., PROTACs) for BCLAF1

  • Exploration of nanotechnology-based delivery systems for BCLAF1-targeting therapeutics

• Experimental Models for Immunotherapy Research:

  • Creation of patient-derived xenografts with varying BCLAF1 expression levels

  • Development of humanized mouse models to study BCLAF1's impact on immune cell function

  • Establishment of 3D organoid cultures to better recapitulate tumor-immune interactions

Technical Innovations for BCLAF1 Detection in Immunotherapy Research: